News Sentiment

ENLV sentiment intelligence

Enlivex Therapeutics Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.86 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-13.3% over one week, -31.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction -13.3% Price reacting lower
Trend fit Trend inactive -31.8% over four weeks
Fair value -68.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 36
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 10
TradingKey 8
simplywall.st 3
The Manila Times 2
GuruFocus 2
MT Newswires 2
marketscreener.com 2

Event Lens

What the news is about

Classified themes
Market update 38
Earnings 13
Balance sheet 3
Capital return 2
Analyst action 1
Deals and strategy 1
Guidance 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
The Manila Times Direct company coverage

Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis

Enlivex Ltd. has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its immunotherapy Allocetra™ to treat age-related knee osteoarthritis in patients aged 64 and older. This designation, based on positive Phase I/IIa trial data, streamlines the development

Tone
Positive 92/100
Event
Market update
Published
14 Jul 2026 04:11
Source
The Manila Times
Market source Direct company coverage

Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Enlivex Ltd. (ENLV) has recently experienced a 31.7% loss in share value over four weeks, placing it in oversold territory according to its Relative Strength Index (RSI) of 19.3. This technical indicator, combined with rising earnings estimates from Wall Street analysts and a Zac

Tone
Positive 71/100
Event
Earnings
Published
13 Jul 2026 13:35
Source
Market source
Stock Titan Direct company coverage

Enlivex (ENLV) wins FDA RMAT designation for Allocetra in age-related knee osteoarthritis

Enlivex Ltd. announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its immunotherapy drug, Allocetra™, for treating age-related symptomatic knee osteoarthritis in patients 64 and older. This designation, based on positive Phase I/IIa tria

Tone
Positive 74/100
Event
Market update
Published
13 Jul 2026 11:40
Source
Stock Titan
Stock Titan Direct company coverage

FDA flags Enlivex’s Allocetra as potential new option for painful knee osteoarthritis

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Enlivex's Allocetra for age-related knee osteoarthritis in patients 64 and older, aiming to accelerate its development. This designation was based on positive Phase I/IIa trial data showing significa

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 11:40
Source
Stock Titan
Investing.com Canada Direct company coverage

Exclusive: FDA grants RMAT designation to Enlivex’s Allocetra for knee OA

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Enlivex's experimental immunotherapy Allocetra for age-related knee osteoarthritis in patients aged 64 and older. This designation is expected to provide the biotech company with enhanced access to t

Tone
Positive 95/100
Event
Market update
Published
13 Jul 2026 10:40
Source
Investing.com Canada
www.marketscreener.com Direct company coverage

Enlivex: Shareholders Board Members Managers and Company Profile | IL0011319527

This article provides a comprehensive company profile for Enlivex Ltd. (IL0011319527), an Israel-based clinical-stage macrophage reprogramming immunotherapy company. It details the company's business description, key executives, board members, major shareholders, and financial ov

Tone
Positive 70/100
Event
Market update
Published
11 Jul 2026 03:39
Source
www.marketscreener.com
The Manila Times Direct company coverage

Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026

Enlivex Ltd. announced a 1-for-15 reverse stock split of its ordinary shares, effective July 9, 2026. This action will combine every fifteen ordinary shares into one, reducing the total number of outstanding shares and proportionately adjusting par value, exercise prices, and the

Tone
Negative 38/100
Event
Market update
Published
07 Jul 2026 14:12
Source
The Manila Times
Investing.com Nigeria Direct company coverage

Enlivex announces 1-for-15 reverse stock split effective Wednesday By Investing.com

Enlivex Ltd. announced a 1-for-15 reverse stock split of its ordinary shares, effective Wednesday, July 9, 2026, to address its stock trading near a 52-week low. This adjustment will reduce the number of authorized shares and outstanding ordinary shares, but will not affect share

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 14:12
Source
Investing.com Nigeria
AD HOC NEWS Direct company coverage

Enlivex Therapeutics outlines its immunotherapy approach as a clinical-stage biotech

Enlivex Therapeutics is a clinical-stage biotechnology company focused on developing immunotherapy candidates for severe inflammatory conditions and oncology, with shares traded on Nasdaq. The company's strategy involves modulating immune cell behavior to address unmet medical ne

Tone
Positive 67/100
Event
Market update
Published
07 Jul 2026 13:52
Source
AD HOC NEWS
GuruFocus Direct company coverage

Enlivex (ENLV) Implements Reverse Stock Split

Enlivex Ltd (ENLV) announced a 1-for-15 reverse stock split effective July 9, 2026, a strategic move to increase its share price and comply with Nasdaq listing requirements. The biotechnology company, focused on developing Allocetra for osteoarthritis, has a P/E ratio of 0.1x, po

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 13:42
Source
GuruFocus
Stock Titan Direct company coverage

Enlivex to shrink share count 15-to-1 on July 9 as Nasdaq trading continues

Enlivex (Nasdaq: ENLV) announced a 1-for-15 reverse stock split of its ordinary shares, effective July 9, 2026, to maintain Nasdaq listing compliance. This action will reduce the number of outstanding shares from 252,480,222 to approximately 16,832,015 and increase the par value

Tone
Negative 28/100
Event
Market update
Published
07 Jul 2026 12:12
Source
Stock Titan
Stock Titan Direct company coverage

Enlivex (Nasdaq: ENLV) enacts 1-for-15 reverse split and cuts share count

Enlivex Ltd. (Nasdaq: ENLV) announced a 1-for-15 reverse stock split, effective July 9, 2026, to consolidate its ordinary shares. This action will reduce authorized shares from 2.375 billion to approximately 158.3 million and outstanding shares from 252.48 million to about 16.83

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 12:12
Source
Stock Titan
Stock Titan Direct company coverage

Enlivex (NASDAQ: ENLV) highlights RAIN listing on Gate and $1.14B treasury

Enlivex Ltd. (NASDAQ: ENLV) announced that its primary treasury asset, the RAIN token, is expected to be listed on the Gate cryptocurrency exchange on June 24, 2026, at 10:00 AM UTC. This listing aims to increase RAIN's accessibility, global reach, and liquidity, supporting Enliv

Tone
Positive 64/100
Event
Balance sheet
Published
24 Jun 2026 12:12
Source
Stock Titan
TradingKey Direct company coverage

Enlivex Therapeutics Ltd (ENLV) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Enlivex Therapeutics Ltd (ENLV), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. The analysis suggests that the stock is currently trading

Tone
Negative 35/100
Event
Market update
Published
23 Jun 2026 11:10
Source
TradingKey
Investing.com South Africa Direct company coverage

Form 6K Enlivex Therapeutics Ltd For: 22 June By Investing.com

This article reports on the filing of Form 6K by Enlivex Therapeutics Ltd for June 22nd. The filing is brief and includes the stock ticker ENLV, which experienced a slight decline. The page also features various financial market data and related news.

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 08:10
Source
Investing.com South Africa
TradingKey Direct company coverage

Enlivex Therapeutics Ltd (ENLV) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Enlivex Therapeutics Ltd (ENLV), noting that no specific risk assessment score is currently available, but the industry average is 3.36. It highlights the company's beta value of 1.67, indicating higher volatility compared to the S&P 50

Tone
Negative 35/100
Event
Market update
Published
23 Jun 2026 05:40
Source
TradingKey
Quiver Quantitative Direct company coverage

Enlivex Reports $1.14 Billion Value in RAIN Token Holdings as of June 20, 2026

Enlivex Ltd. announced holdings of 79.5 billion RAIN tokens valued at $1.14 billion as of June 20, 2026, contributing to a Treasury NAV per Share of $4.67. The company employs a dual strategy, advancing its Allocetra™ immunotherapy and managing a prediction markets treasury throu

Tone
Positive 62/100
Event
Market update
Published
22 Jun 2026 12:50
Source
Quiver Quantitative
Stock Titan Direct company coverage

[6-K] Enlivex Ltd. Current Report (Foreign Issuer) | ENLV SEC Filing - Form 6-K

Enlivex Ltd. filed a Form 6-K report, updating on its digital asset treasury. As of June 20, 2026, the company held 79.57 billion RAIN tokens, valued at approximately $1.14 billion, leading to an unaudited Treasury NAV per Share of $4.67. Enlivex emphasizes its dual strategy of a

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 12:39
Source
Stock Titan
AD HOC NEWS Direct company coverage

ENLV Stock - weekly outlook with no verified hook

This article provides a weekly outlook for Enlivex Therapeutics (ENLV) stock, noting the absence of a live-verifiable corporate hook in recent search results. It focuses on the company's clinical-stage profile as a macrophage reprogramming immunotherapy business and highlights th

Tone
Neutral 50/100
Event
Earnings
Published
20 Jun 2026 15:40
Source
AD HOC NEWS
TradingKey Direct company coverage

Enlivex Therapeutics Ltd (ENLV) Earnings Forecast: Future EPS & Revenue Growth Estimates

Enlivex Therapeutics Ltd (ENLV) has an earnings forecast score of 8.00, placing it well within its industry. Analysts predict a price target of $7.00, with a consensus "Buy" rating based on one analyst's assessment. The company's previous EPS was -$0.09, with the next quarter's E

Tone
Positive 71/100
Event
Earnings
Published
19 Jun 2026 02:19
Source
TradingKey
TradingKey Direct company coverage

Enlivex Therapeutics Ltd (ENLV) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Enlivex Therapeutics Ltd's (ENLV) financial health, highlighting its weak financial status and low operating efficiency within the Biotechnology & Medical Research industry. The company's financial score is 5.38, ranking it poorly compared to

Tone
Negative 30/100
Event
Market update
Published
18 Jun 2026 23:10
Source
TradingKey